A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part

MLA

Mitsuya Ishikawa, et al. A Randomized Phase II/III Trial of Conventional Paclitaxel and Carboplatin with/without Bevacizumab versus Dose-Dense Paclitaxel and Carboplatin with/without Bevacizumab, in Stage IVB, Recurrent, or Persistent Cervical Carcinoma (JCOG1311): Results of the Phase II Part. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a345a15da77bf7ca2b8c73f3332d3391&authtype=sso&custid=ns315887. Accessed 5 Feb. 2025.

APA

Mitsuya Ishikawa, Taro Shibata, Nobuo Yaegashi, Shin Nishio, Toshio Takada, Masahiro Kagabu, Hideki Tokunaga, Wataru Kudaka, Masahiko Mori, Takashi Iwata, Michihiro Tanikawa, Koji Horie, Hiroaki Kobayashi, & Ryo Kitagawa. (n.d.). A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part.

Chicago

Mitsuya Ishikawa, Taro Shibata, Nobuo Yaegashi, Shin Nishio, Toshio Takada, Masahiro Kagabu, Hideki Tokunaga, et al. 2025. “A Randomized Phase II/III Trial of Conventional Paclitaxel and Carboplatin with/without Bevacizumab versus Dose-Dense Paclitaxel and Carboplatin with/without Bevacizumab, in Stage IVB, Recurrent, or Persistent Cervical Carcinoma (JCOG1311): Results of the Phase II Part.” Accessed February 5. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a345a15da77bf7ca2b8c73f3332d3391&authtype=sso&custid=ns315887.